➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
McKesson
Johnson and Johnson
Baxter
Colorcon

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CAPMATINIB HYDROCHLORIDE

« Back to Dashboard

All Clinical Trials for Capmatinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting Novartis Phase 2 2016-05-01 This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting Massachusetts General Hospital Phase 2 2016-05-01 This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
NCT03040973 Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study Not yet recruiting Novartis Pharmaceuticals Phase 4 2017-05-31 The rollover study will provide continued treatment and assessment of long-term safety follow-up in patients receiving capmatinib (INC280) in a Novartis sponsored study and in the opinion of the Investigator would benefit from continued treatment.
NCT03240393 Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Not yet recruiting Novartis Pharmaceuticals Phase 2 2017-11-30 A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Capmatinib Hydrochloride

Condition Name

Condition Name for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 4
Non-small Cell Lung Cancer (NSCLC) 2
Triple Negative Breast Cancer (TNBC) 1
Soft Tissue Sarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 8
Lung Neoplasms 6
Carcinoma 2
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Capmatinib Hydrochloride

Trials by Country

Trials by Country for Capmatinib Hydrochloride
Location Trials
United States 4
Spain 2
France 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Capmatinib Hydrochloride
Location Trials
Arkansas 1
California 1
Michigan 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Capmatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 10
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Capmatinib Hydrochloride

Sponsor Name

Sponsor Name for Capmatinib Hydrochloride
Sponsor Trials
Novartis Pharmaceuticals 11
Commissariat A L'energie Atomique 1
CIC-EC 1401/EUCLID 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Capmatinib Hydrochloride
Sponsor Trials
Industry 12
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Colorcon
AstraZeneca
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.